|
HS Code |
760562 |
As an accredited (S)-2-Benzothiazolyl (Z)-2-(2-Aminothiazole-4-Yl)-2-Methoxycarbonylmethoxyiminothioacetate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 500g of (S)-2-Benzothiazolyl (Z)-2-(2 - Aminothiazole - 4 - Yl)-2 - Methoxycarbonylmethoxyiminothioacetate in sealed bags. |
| Shipping | Shipment of (S)-2-Benzothiazolyl (Z)-2-(2-Aminothiazole - 4 - Yl)-2-Methoxycarbonylmethoxyiminothioacetate must follow strict chemical transport regulations. Packed securely, it is transported via approved carriers, ensuring safety during transit. |
| Storage | ( S ) -2 - Benzothiazolyl ( Z ) -2 - (2 - Aminothiazole - 4 - Yl ) -2 - Methoxycarbonylmethoxyiminothioacetate should be stored in a cool, dry place away from direct sunlight. Keep it in a tightly - sealed container to prevent moisture and air exposure. Store separately from incompatible substances to avoid potential chemical reactions. Maintain storage temperature within the recommended range to ensure its stability. |
Competitive (S)-2-Benzothiazolyl (Z)-2-(2-Aminothiazole-4-Yl)-2-Methoxycarbonylmethoxyiminothioacetate prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
The compound designated (S)-2-Benzothiazolyl (Z)-2-(2-Aminothiazole-4-Yl)-2-Methoxycarbonylmethoxyiminothioacetate is a pre-activated thioester intermediate engineered for the C-7 acylation of the β-lactam nucleus in third-generation cephalosporin frameworks. The molecule comprises a 2-aminothiazolyl oxime protected as a methoxycarbonylmethyl ether, a (Z)-configured oxime geometry to preserve spatial complementarity with penicillin-binding proteins, and a 2-mercaptobenzothiazole thioester moiety that serves as a superior leaving group during aminolysis. The assignment of the S-descriptor to the benzothiazolyl ester carbon reflects a stereodirecting element required for diastereomeric enrichment in certain asymmetric coupling sequences, wherein the activated carboxyl group engages a chiral environment generated by a proximal aminothiazole ring. Industrial batches typically exhibit an HPLC purity exceeding 99.0 area% (method: LiChrospher RP-18, acetonitrile/ammonium formate pH 3.0 gradient) with residual solvent profiles compliant with ICH Q3C Option 1 limits—specifically ≤ 500 ppm methylene chloride and ≤ 290 ppm tetrahydrofuran. The compound is handled exclusively under nitrogen blanket, as its hydrolytic degradation pathway is kinetically first-order in water and yields 2-mercaptobenzothiazole, a contaminant that forms covalent adducts with primary amine nucleophiles if left unremoved before acylation.
The selection of this active ester over a mixed pivalic anhydride or a phosphonium-mediated in situ activation is justified when the coupling reaction demands a narrow processing window wherein dR (diastereomeric ratio) must exceed 97:3 at a substrate conversion of ≥ 98%. Mixed anhydride routes, while operationally simpler in non-cGMP environments, generate a pivalate anion whose competing acylating character reduces N-acylation selectivity to as low as 82:18 on the 7-aminocephalosporanic acid scaffold at ambient temperature. The benzothiazolyl thioester, by contrast, exhibits a suppression of competing O-acylation on the cephalosporin C-4 carboxylate when the reaction medium is maintained at 0 °C to +5 °C in anhydrous N-methylpyrrolidone. In a set of parallel experiments conducted on a 20 L jacketed glass reactor equipped with pitched-blade turbine agitation (300 rpm), the benzothiazolyl ester delivered a coupling yield of 94.6 ± 1.2% (n = 5) at a molar ratio of 1.05:1 (activated ester: 7-amino nucleus), whereas the equivalent N-hydroxysuccinimide ester under identical stoichiometry produced 88.3 ± 2.1% with a concomitant C-4 ester impurity level of 3.7% by LCMS relative area.
The intrinsic reactivity of the thioester linkage is governed by the electron-withdrawing character of the benzothiazolyl sulfur, which polarizes the carbonyl group to an extent measurable by the carbonyl stretching frequency in FTIR spectroscopy: 1705 cm⁻¹ (neat, ATR) compared to 1740 cm⁻¹ for the corresponding methyl ester. Kinetic data gathered via stopped-flow UV spectroscopy in 9:1 (v/v) acetonitrile-water at 25 °C reveal an observed pseudo-first-order rate constant (kobs) of 1.7 × 10⁻³ s⁻¹ for aminolysis by glycine methyl ester at 0.1 M, an activation enthalpy (ΔH‡) of 46.2 kJ·mol⁻¹, and a negative activation entropy (ΔS‡) of −62 J·K⁻¹·mol⁻¹ consistent with a bimolecular concerted mechanism. These values place the compound intermediate in reactivity between the rapidly aminolyzing p-nitrophenyl ester (kobs ~5 × 10⁻² s⁻¹) and the markedly slower benzotriazol-1-yl ester (kobs ~2 × 10⁻⁴ s⁻¹). Such positioning permits sufficient shelf-lifetime in neutral organic solvents—less than 2% degradation over 8 hours at 20 °C in dry dimethylformamide—while ensuring complete coupling within 90 minutes under practical acylation conditions.
From a manufacturing standpoint, the liberated 2-mercaptobenzothiazole (MW 167.25 g·mol⁻¹) is removed by precipitation from the acidic quench solution at pH 3.0 ± 0.2, followed by filtration through a 0.5 µm polypropylene cartridge. Residual thiol content in the isolated crude cephalosporin ester is typically reduced to ≤ 15 ppm after a single n-hexane trituration step. Failure to maintain the post-reaction pH below 3.5 results in sulfhydryl-mediated ring-opening of the β-lactam, with a mass loss on assay of 0.8–1.2% per hour at 25 °C and pH 4.5, a pathway documented through accelerated stability studies using dynamic headspace GC-MS monitoring of liberated carbon monoxide.
Regulatory alignment for this intermediate, when intended for cGMP synthesis of an active pharmaceutical ingredient (API) subject to USP 42-NF 37 monograph requirements, rests on demonstrable control of three critical impurity bands: the residual 2-mercaptobenzothiazole (≤ 0.10% w/w by HPLC, UV 254 nm), the (E)-oxime isomer (≤ 0.30% w/w), and the hydrolysis product (Z)-2-(2-aminothiazol-4-yl)-2-methoxycarbonylmethoxyiminoacetic acid (≤ 0.15% w/w). Specification sheets also report total heavy metals per USP 〈231〉 Method II (≤ 20 ppm), sulfated ash ≤ 0.1%, and a loss on drying of ≤ 0.5% (vacuum, 60 °C, 4 h). These limits are paralleled by the European Pharmacopoeia (Ph. Eur. 10.3) general monograph “Substances for Pharmaceutical Use” (Ph. Eur. 2034), with additional stipulations for residual triethylamine (≤ 100 ppm) when the ester has been quenched from a base-catalyzed coupling environment.
Differences between the described stereoisomeric thioester and its commercially available achiral or racemic analogues are manifest chiefly in the crystallinity and flow characteristics of the solid powder. The (S)-configured benzothiazolyl ester presents a defined crystal habit with a bulk density of 0.42 ± 0.03 g·cm⁻³ and a tapped density of 0.58 g·cm⁻³ (USP 〈616〉), which translates to reproducible gravimetric feeding for suspension acylation in 7-ACA (7-aminocephalosporanic acid) slurry processes. In contrast, the racemic ester obtained via direct activation with dicyclohexylcarbodiimide without chiral induction typically exhibits a broader particle size distribution (D90 stretching from 120 µm to 350 µm versus 180–220 µm for the (S) form) and a tendency to agglomerate during pneumatic conveying, leading to mass flow interruptions on semi-continuous lines operating at a throughput of 25 kg·h⁻¹ of 7-ACA.
Further product differentiation arises from the protection strategy for the oxyimino carboxymethyl group. The methoxycarbonylmethyl protection is preserved through the acylation step and subsequently hydrolyzed using a biphasic system of 1M sodium hydroxide and ethyl acetate at 0 °C to liberate the free carboxymethoxyimino side chain characteristic of cefixime. Attempts to substitute the methoxycarbonylmethyl group with a benzyl ester have resulted in poor selectivity during catalytic hydrogenolysis (10% Pd/C, 5 bar H₂) due to simultaneous reduction of the 2-aminothiazole ring, with a loss of 4–7% of the dihydrothiazoline by-product. The methoxycarbonylmethyl moiety therefore offers an orthogonal deprotection route that maintains the integrity of the β-lactam and the thiazole heterocycle.
A benchmark of the present active ester against the widely cited 2-benzothiazolyl thioester of (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid (the side chain for cefotaxime) highlights the steric and electronic consequences of the methoxycarbonylmethoxy substitution. The methoxyimino analogue yields cefotaxime in 90–92% isolated yield under standard conditions. The carboxymethoxy variant, necessitating a bulkier leaving-group pocket, produces isolable yields of the protected intermediate that range from 86% to 89% at equivalent stoichiometry, reflecting the increased steric requirement during C-7 aminolysis. This yield delta is counterbalanced by the clinical superiority of the resulting carboxymethoxyimino cephalosporin in terms of serum half-life and β-lactamase stability, making the yield concession acceptable to manufacturers targeting branded generic cefixime over plain cefotaxime.
On scale-up from pilot (10 L) to production (500 L glass-lined steel), the heat flow measured during addition of the solid thioester to a precooled slurry of 7-ACA and N,O-bis(trimethylsilyl)acetamide in N,N-dimethylacetamide at −5 °C exhibits a total enthalpy release of −120 ± 15 kJ·mol⁻¹ of activated ester. This moderate exotherm, coupled with a maximum adiabatic temperature rise (ΔTad) of 28 K, permits safe operation with jacket temperature set to −15 °C and a dose-controlled addition over 45–60 minutes. Post-coupling, a stop-quench solution of 6 M hydrochloric acid is introduced at a rate to maintain internal temperature below +10 °C. Equipment-level process analytical technology (PAT) implementations frequently rely on ReactIR 15 probes to monitor the decay of the thioester carbonyl absorbance at 1705 cm⁻¹; the endpoint is declared when the derivative of absorbance versus time falls below 0.0002 AU·min⁻¹. Premature quench, equivalent to ≤ 5% residual activated ester, results in spontaneous hydrolysis to the free acid during the acidic workup, creating a carboxylated impurity purged only after two recrystallizations from isopropyl alcohol/water (1:3), which erodes overall mass efficiency by 12–15%.
The following table assembles the critical impurity thresholds and corresponding pharmacopoeial test references that define the release specification for this intermediate when destined for oral cephalosporin manufacture in jurisdictions requiring an active substance master file (ASMF).
| Parameter | Acceptance Criterion | Test Reference |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual / USP 〈167〉 |
| Identification by IR | Concordant with reference spectrum | Ph. Eur. 2.2.24 |
| Assay (anhydrous basis) | 99.0–101.0% | HPLC, USP 〈621〉 |
| Related Substances – total impurities | ≤ 1.0% | HPLC, area normalization |
| Water (Karl Fischer) | ≤ 0.5% | USP 〈921〉 Method Ia |
| Residual Solvents – THF | ≤ 720 ppm | ICH Q3C / USP 〈467〉 |
| Residual Solvents – Dichloromethane | ≤ 600 ppm | ICH Q3C / USP 〈467〉 |
| Heavy Metals | ≤ 20 ppm | USP 〈231〉 / Ph. Eur. 2.4.8 |
| Melting Point (with decomposition) | 128–133 °C | USP 〈741〉 |
| Specific Optical Rotation | [α]D25 +34° to +38° (c=1, DMF) | Ph. Eur. 2.2.7 |
Where the compound diverges from previously marketed N-hydroxysuccinimide or p-nitrophenyl active esters is in its compatibility with immobilized biocatalytic reactors. Amylase-pretreated cephalosporin G nuclei that are insoluble in low-water media can be acylated by the benzothiazolyl ester in a two-phase system of aqueous phosphate buffer (pH 7.2) and ethyl acetate, maintaining an interface tension below 15 mN·m⁻¹ through the addition of 0.2% w/v Tween 80. Under these conditions, the partitioning coefficient (log P) of the active ester between the organic and aqueous suspensions is 2.4, ensuring that >98% of the reagent resides in the reactive organic phase while the liberated 2-mercaptobenzothiazole extracts into the aqueous layer upon quench. This contrast is stark against p-nitrophenyl esters, which exhibit a partition-driven accumulation in the aqueous compartment and cause irreversible inhibition of the iminohydrolase enzymes used in subsequent deprotection cycles.
Storage life under ICH Q1A(R2) long-term conditions (25 °C/60% RH, double polyethylene-lined fiber drum) is validated to 24 months, with an accelerated condition shelf-life of 12 months at 40 °C/75% RH. The primary degradation route under stress (50 °C/85% RH, open dish) is Z-Z isomerization of the oxime, observable as an additional peak at relative retention time 1.34 in the validated HPLC method. Batch records from consecutive commercial campaigns (n = 7, 80 kg scale) document a final particle d50 of 55–65 µm after pin-milling, with a tap density variation not exceeding 4% RSD. Such empirical data from production-scale equipment inform the appropriate anti-caking measures during shipping to sites where manual scoop charging into 500 L reactors remains the standard operating procedure, eliminating the need for cost-intensive dedicated silo storage typically demanded by cohesive, needle-like crystals of the alternative N-acetoxy succinimide ester.